Onset of Inattention and Hyperactivity in Children and Adolescents With Epilepsy 6 months After the Diagnosis

Željka Rogač1, Dejan Stevanović2, Sara Bečanović3

  • 1Clinical Centre of Montenegro, Podgorica, Montenegro.

PubMed

Insights

Pediatric epilepsy patients showed increased attention and hyperactivity symptoms 6 months after diagnosis and starting medication. These symptoms emerged even without prior ADHD diagnosis.

Area of Science:

  • Neurology
  • Pediatric Neurology
  • Neurodevelopmental Disorders

Background:

  • Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms are frequently observed in epilepsy.
  • The emergence of ADHD symptoms in pediatric epilepsy patients without comorbid ADHD requires further investigation.

Purpose of the Study:

  • To evaluate inattention and hyperactivity symptoms in children and adolescents with newly diagnosed epilepsy over the first six months.
  • To identify predictors of these symptoms in the early stages of epilepsy management.

Main Methods:

  • A prospective study followed pediatric epilepsy patients for six months post-diagnosis and initiation of antiseizure medications.
  • Behavioral assessments included the Nisonger Child Behavior Rating Form (NCBRF) and the Adverse Event Profile (AEP).
  • Cognitive function was assessed using the Revised Wechsler Intelligence Scale for Children.

Main Results:

  • A significant increase in attention difficulties and a moderate increase in hyperactivity levels were observed.
  • Predictors for inattention included AEP scores, changes in non-verbal intelligence, and baseline/follow-up hyperactivity and attention levels.
  • Hyperactivity was predicted by baseline hyperactivity and follow-up inattention.

Conclusions:

  • Inattention and hyperactivity symptoms significantly emerged six months after epilepsy diagnosis and the commencement of antiseizure medication.
  • These findings highlight the need for monitoring behavioral symptoms in pediatric epilepsy patients.
Abstract

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
132
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
215
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
215
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
424
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
347